Head-to-head evidence
GSK5784283 vs WIN378
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: TSLP · full Asthma pipeline
GSK5784283
Developed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT07712393 (registry estimate)
WIN378
Developed by Windward Bio under a licence from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT05790694 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: July 2027 · NCT07120503 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GSK5784283's landscape · WIN378's landscape